

A large, semi-transparent watermark of the Vizle logo is centered on the page. It consists of the letters 'V' and 'Z' in a stylized font, with a green square containing a white 'V' and 'Z' inside the 'Z'. Below this is the word 'Vizle' in a large, light-colored sans-serif font.

This PDF is generated automatically by **Vizle**.
Slides created *only for a few minutes* of your Video.



For the full PDF, please **Login to Vizle**.

<https://vizle.offnote.co> (Login via Google, top-right)

Stay connected with us:

Join us on **Facebook, Discord, Quora, Telegram**.



GoodCode

vizle

```

</section Three Title</h3>
<p>This is the start of a
<a title="article on relationship
good relationship">

```

```

      <img alt="img" data-bbox="750 384 898 410"/>
      <img alt="img" data-bbox="750 410 898 436"/>
      <img alt="img" data-bbox="750 436 898 462"/>
      <img alt="img" data-bbox="750 462 898 488"/>
      <img alt="img" data-bbox="750 488 898 514"/>
      <img alt="img" data-bbox="750 514 898 540"/>
      <img alt="img" data-bbox="750 540 898 566"/>

```

```

<p>This is the start of a
<a title="article on relationship
good relationship">
</section Three Title</h3>

```

```

      <img alt="img" data-bbox="705 766 889 792"/>
</section Three Title</h3>

```



THE LANCET

Log in Register Subscribe Claim

ARTICLES | VOLUME 395, ISSUE 10242, P1988-1997, JUNE 27, 2020

Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study

Juan Fortea, PhD · Eduard Vilaplana, PhD · Maria Carmona-Iragui, PhD · Bessy Benejam, BSc · Laura Videla, MSc · Isabel Barroeta, PhD · et al. [Show all authors](#) · [Show footnotes](#)

Open Access · Published: June 27, 2020 · DOI: [https://doi.org/10.1016/S0140-6736\(20\)30689-9](https://doi.org/10.1016/S0140-6736(20)30689-9)

Check for updates

PDF [1 MB] Figures Save Share Reprints Request

+999

PlumX Metrics

PIIS0140673620306899.pdf - Foxit Reader

Home Comment View Form Protect Share Connect Help Extras Comment Format

1988

Read Mode Reflow Reverse View Night Mode Text Viewer

Portfolio Rotate View

Guides Rulers Line Weights

AutoScroll Marquee Loupe Magnifier Read

Navigation Panels Status Bar

123 ABC Word Count Review

Articles



Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study



Juan Fortea, Eduard Vilaplana, Maria Carmona-Iragui, Bessy Benejam, Laura Videla, Isabel Barroeta, Susana Fernández, Miren Altuna, Jordi Pegueroles, Victor Montal, Silvia Valldeneu, Sandra Giménez, Sofia González-Ortiz, Laia Muñoz, Teresa Estellés, Ignacio Illán-Gala, Olivia Belbin, Valle Camacho, Liam Reese Wilson, Tiina Annus, Ricardo S Osorio, Sebastián Videla, Sylvain Lehmann, Anthony J Holland, Daniel Akcolea, Jordi Clarimón, Shahid H Zaman, Rafael Blesa*, Alberto Lleó*

Summary

Lancet 2020; 395: 1988-97

See Comment page 1951

Background Alzheimer's disease and its complications are the leading cause of death in adults with Down syndrome. Studies have assessed Alzheimer's disease in individuals with Down syndrome, but the natural history of biomarker changes in Down syndrome has not been established. We characterized the order and timing of changes in biomarkers

Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study

Juan Fortea, Eduard Vilaplana, Maria Carmona-Iragui, Bessy Benejam, Laura Videla, Isabel Barroeta, Susana Fernández, Miren Altuna, Jordi Pegueroles, Victor Montal, Silvia Valldeneu, Sandra Giménez, Sofia González-Ortiz, Laia Muñoz, Teresa Estellés, Ignacio Illán-Gala, Olivia Belbin, Valle Camacho, Liam Reese Wilson, Tiina Annus, Ricardo S Osorio, Sebastián Videla, Sylvain Lehmann, Anthony J Holland, Daniel Alcolea, Jordi Clarimón, Shahid H Zaman, Rafael Blesa*, Alberto Lleó*

Summary

Background Alzheimer's disease and its complications are the leading cause of death in adults with Down syndrome. Studies have assessed Alzheimer's disease in individuals with Down syndrome, but the natural history of biomarker changes in Down syndrome has not been established. We characterised the order and timing of changes in biomarkers of Alzheimer's disease in a population of adults with Down syndrome.

Methods We did a dual-centre cross-sectional study of adults with Down syndrome recruited through a population-based health plan in Barcelona (Spain) and through services for people with intellectual disabilities in Cambridge (UK). Cognitive impairment in participants with Down syndrome was classified with the Cambridge Cognitive Examination for Older Adults with Down Syndrome (CAMCOG-DS). Only participants with mild or moderate disability were included who had at least one of the following Alzheimer's disease measures: apolipoprotein E allele carrier status; plasma concentrations of amyloid β peptides 1–42 and 1–40 and their ratio ($A\beta_{1-42/1-40}$), total tau protein, and neurofilament light chain (NFL); tau phosphorylated at threonine 181 (p-tau), and NFL in cerebrospinal fluid (CSF); and one or more PET with ^{18}F -fluorodeoxyglucose, PET with amyloid tracers, and MRI. Cognitively healthy euploid controls aged up to 75 years who had no biomarker abnormalities were recruited from the Sant Pau Initiative

Lancet 2020; 395: 1988–97
See Comment page 1951
*Contributed equally
Barcelona Down Medical Center, Fundació Catalana de Síndrome de Down, Barcelona, Spain (J Fortea PhD, M Carmona-Iragui PhD, B Benejam BSc, L Videla MSc, S Fernández MD); Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona,

V
1968
Home
Comment
View
Form
Protect
Share
Connect
Help
Extras
Comment Format
Tell me what you want to do..
Find

Vizle
Select
Previous View
Next View
Zoom
Tools
Go To
Document Views
Read Mode
Reflow
Reverse View
Night Mode
Text Viewer
Portfolio
Rotate View
Guides
Rulers
Line Weights
Page Display
AutoScroll
Marquee
Loupe
Magnifier
Assistant
Read
Navigation Panels
Status Bar
View Setting
123 ABC
Word Count
Review

Start
PIIS014067362030689...
Convert PDF 2 Word
PDF
Word

M Carmona-Iragui PhD, B Benejam BSc, L Videla MSc, S Fernández MD; Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain (J Fortea, E Vilaplana PhD, M Carmona-Iragui, B Benejam, L Videla, I Barroeta PhD, M Altuna MD, J Pegueroles MSc, V Montal MSc, S Valldeneu, L Muñoz BSc, T Estellés MD, I Illán-Gala PhD, O Belbin PhD, D Alcolea PhD, J Clarimón PhD, R Blesa PhD, A Lleó PhD); Center of Biomedical Investigation Network for Neurodegenerative Diseases, Madrid, Spain (J Fortea, E Vilaplana, M Carmona-Iragui, B Benejam, L Videla, I Barroeta, M Altuna, J Pegueroles, V Montal, S Valldeneu, L Muñoz, T Estellés, I Illán-Gala, O Belbin, D Alcolea, J Clarimón, R Blesa, A Lleó); Multidisciplinary Sleep Unit, Respiratory Department

based neuroplan in Barcelona (Spain) and through services for people with intellectual disabilities in Cambridge (UK). Cognitive impairment in participants with Down syndrome was classified with the Cambridge Cognitive Examination for Older Adults with Down Syndrome (CAMCOG-DS). Only participants with mild or moderate disability were included who had at least one of the following Alzheimer's disease measures: apolipoprotein E allele carrier status; plasma concentrations of amyloid β peptides 1-42 and 1-40 and their ratio ($A\beta_{1-42/1-40}$), total tau protein, and neurofilament light chain (NFL); tau phosphorylated at threonine 181 (p-tau), and NFL in cerebrospinal fluid (CSF); and one or more of PET with ^{18}F -fluorodeoxyglucose, PET with amyloid tracers, and MRI. Cognitively healthy euploid controls aged up to 75 years who had no biomarker abnormalities were recruited from the Sant Pau Initiative on Neurodegeneration. We used a first-order locally estimated scatterplot smoothing curve to determine the order and age at onset of the biomarker changes, and the lowest ages at the divergence with 95% CIs are also reported where appropriate.

Findings Between Feb 1, 2013, and June 28, 2019 (Barcelona), and between June 1, 2009, and Dec 31, 2014 (Cambridge), we included 388 participants with Down syndrome (257 [66%] asymptomatic, 48 [12%] with prodromal Alzheimer's disease, and 83 [21%] with Alzheimer's disease dementia) and 242 euploid controls. CSF $A\beta_{1-42/1-40}$ and plasma NFL values changed in individuals with Down syndrome as early as the third decade of life, and amyloid PET uptake changed in the fourth decade. ^{18}F -fluorodeoxyglucose PET and CSF p-tau changes occurred later in the fourth decade of life, followed by hippocampal atrophy and changes in cognition in the fifth decade of life. Prodromal Alzheimer's disease was diagnosed at a median age of 50.2 years (IQR 47.5-54.1), and Alzheimer's disease dementia at 53.7 years (49.5-57.2). Symptomatic Alzheimer's disease prevalence increased with age in individuals with Down syndrome, reaching 90-100% in the seventh decade of life.

Interpretation Alzheimer's disease in individuals with Down syndrome has a long preclinical phase in which biomarkers follow a predictable order of changes over more than two decades. The similarities with sporadic and autosomal dominant Alzheimer's disease and the prevalence of Down syndrome make this population a suitable

Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain (J Fortea, E Vilaplana PhD, M Carmona-Iragui, B Benejam, L Videla, I Barroeta PhD, M Altuna MD, J Pegueroles MSc, V Montal MSc, S Valdenu, L Muñoz BSc, T Estellés MD, I Illán-Gala PhD, O Belbin PhD, D Alcolea PhD, J Clarimón PhD, R Blesa PhD, A Lleó PhD); Center of Biomedical Investigation Network for Neurodegenerative Diseases, Madrid, Spain (J Fortea, E Vilaplana, M Carmona-Iragui, B Benejam, L Videla, I Barroeta, M Altuna, J Pegueroles, V Montal, S Valdenu, L Muñoz, T Estellés, I Illán-Gala, O Belbin, D Alcolea, J Clarimón, R Blesa, A Lleó); Multidisciplinary Sleep Unit, Respiratory Department (S Giménez PhD), and Nuclear Medicine Department (V Camacho PhD), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Parc de Salut, Hospital del Mar, Barcelona, Spain (S González-Ortiz PhD);

(CSF); and one or more of PET with ^{18}F -fluorodeoxyglucose, PET with amyloid tracers, and MRI. Cognitively healthy euploid controls aged up to 75 years who had no biomarker abnormalities were recruited from the Sant Pau Initiative on Neurodegeneration. We used a first-order locally estimated scatterplot smoothing curve to determine the order and age at onset of the biomarker changes, and the lowest ages at the divergence with 95% CIs are also reported where appropriate.

Findings Between Feb 1, 2013, and June 28, 2019 (Barcelona), and between June 1, 2009, and Dec 31, 2014 (Cambridge), we included 388 participants with Down syndrome (257 [66%] asymptomatic, 48 [12%] with prodromal Alzheimer's disease, and 83 [21%] with Alzheimer's disease dementia) and 242 euploid controls. CSF $\text{A}\beta_{42/40}$ and plasma NFL values changed in individuals with Down syndrome as early as the third decade of life, and amyloid PET uptake changed in the fourth decade. ^{18}F -fluorodeoxyglucose PET and CSF p-tau changes occurred later in the fourth decade of life, followed by hippocampal atrophy and changes in cognition in the fifth decade of life. Prodromal Alzheimer's disease was diagnosed at a median age of 50.2 years (IQR 47.5–54.1), and Alzheimer's disease dementia at 53.7 years (49.5–57.2). Symptomatic Alzheimer's disease prevalence increased with age in individuals with Down syndrome, reaching 90–100% in the seventh decade of life.

Interpretation Alzheimer's disease in individuals with Down syndrome has a long preclinical phase in which biomarkers follow a predictable order of changes over more than two decades. The similarities with sporadic and autosomal dominant Alzheimer's disease and the prevalence of Down syndrome make this population a suitable target for Alzheimer's disease preventive treatments.

Funding Instituto de Salud Carlos III, Fundació Bancaria La Caixa, Fundació La Marató de TV3, Medical Research Council, and National Institutes of Health.

Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0

V
PIIS0140673620306899.pdf - Foxit Reader
Highlight Tool

Home Comment View Form Protect Share Connect Help Extras Comment Format Tell me what you want to do...

1988
Read Mode
Reflow
Reverse View
Night Mode
Text Viewer
Portfolio
Rotate View
Guides
Rulers
Line Weights
AutoScroll
Marquee
Loupe
Magnifier
Read
Navigation Panels
Status Bar
123 ABC
Word Count

Tools Go To Document Views Page Display Assistant View Setting Review

Start PIIS014067362030689... x Convert PDF 2 Word PDF Word

V Montal MSc, S Valdenu, L Muñoz BSc, T Estellés MD, I Illán-Gala PhD, O Belbin PhD, D Alcolea PhD, J Clarimón PhD, R Blesa PhD, A Lleó PhD; Center of Biomedical Investigation Network for Neurodegenerative Diseases, Madrid, Spain (J Fortea, E Vilaplana, M Carmona-Iragui, B Benejam, L Videla, I Barroeta, M Altna, J Peguerols, V Montal, S Valdenu, L Muñoz, T Estellés, I Illán-Gala, O Belbin, D Alcolea, J Clarimón, R Blesa, A Lleó); Multidisciplinary Sleep Unit, Respiratory Department (S Giménez PhD), and Nuclear Medicine Department (V Camacho PhD), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Parc de Salut, Hospital del Mar, Barcelona, Spain (S González-Ortiz PhD); Cambridge Intellectual and Developmental Disabilities Research Group, Department of Psychiatry, Douglas House, University of Cambridge, Cambridge, UK (L R Wilson PhD, T Annus PhD, A J Holland MD,

Findings Between Feb 1, 2013, and June 28, 2019 (Barcelona), and between June 1, 2009, and Dec 31, 2014 (Cambridge), we included 388 participants with Down syndrome (257 [66%] asymptomatic, 48 [12%] with prodromal Alzheimer's disease, and 83 [21%] with Alzheimer's disease dementia) and 242 euploid controls. CSF $A\beta_{42,p=48}$ and plasma NFL values changed in individuals with Down syndrome as early as the third decade of life, and amyloid PET uptake changed in the fourth decade. ^{18}F -fluorodeoxyglucose PET and CSF p-tau changes occurred later in the fourth decade of life, followed by hippocampal atrophy and changes in cognition in the fifth decade of life. Prodromal Alzheimer's disease was diagnosed at a median age of 50.2 years (IQR 47.5–54.1), and Alzheimer's disease dementia at 53.7 years (49.5–57.2). Symptomatic Alzheimer's disease prevalence increased with age in individuals with Down syndrome, reaching 90–100% in the seventh decade of life.

Interpretation Alzheimer's disease in individuals with Down syndrome has a long preclinical phase in which biomarkers follow a predictable order of changes over more than two decades. The similarities with sporadic and autosomal dominant Alzheimer's disease and the prevalence of Down syndrome make this population a suitable target for Alzheimer's disease preventive treatments.

Funding Instituto de Salud Carlos III, Fundació Bancaria La Caixa, Fundació La Marató de TV3, Medical Research Council, and National Institutes of Health.

Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.

Introduction Down syndrome (also referred to as trisomy 21) is the most frequent form of genetic developmental and particularly Alzheimer's disease. The lifetime risk of Alzheimer's disease in people with Down syndrome is now more than 90%,¹ and the disease is the leading cause

1988 (1 / 10)
144.71%

This PDF is generated automatically by **Vizle**.
Slides created *only for a few minutes* of your Video.



For the full PDF, please **Login to Vizle**.

<https://vizle.offnote.co> (Login via Google, top-right)

Stay connected with us:

Join us on **Facebook, Discord, Quora, Telegram**.